Systemic lupus erythematosis (SLE), scleroderma, myositis and Sjӧgren's sydrome (SS) are rare, complex, multi-systemic rheumatic diseases associated with significant morbidity and mortality. Thorough assessments of disease activity are required to guide clinical management and assess response to new therapies in clinical trials. In this article, we shall review the commonly used outcome measures to assess this group of diseases and discuss the limitations of their use.
INTRODUCTION
Outcome measures form a crucial component of clinical practice and research. A standardised assessment of disease activity provides an accurate trend of disease activity overtime and prompts changes in patient's management. Over the last decade, there has been burgeoning research into the pathogenesis of SLE, scleroderma, autoimmune myopathies and SS, leading to the development of novel therapeutic targets. Robust measures of disease activity are required to accurately assess the efficacy of these new therapies in clinical trials. The Outcomes Measures in Rheumatologic Trials group (OMERACT) (Tugwell et al., 2007) have established clear constructs for outcome measures; stating that they should be valid, sensitive, reproducible, sensitive to change and feasible.
In this article, we shall review the common outcome measures used to assess this group of diseases and the limitations of their use.
Systemic lupus erythematosus (SLE)
SLE is a chronic multisystem autoimmune disease with a heterogeneous pattern of clinical and serological manifestations. Pathogenesis of the disease involves a complex interaction between gene susceptibility, hormonal influences and certain environmental triggers which induce autoantibody production (Rahman and Isenberg, 2008) . It has an overall incidence of 4.9-5.5 and prevalence of 72.8-97 in recent UK and US population estimates with a 6-10 fold female predominance (Somers et al., 2014) . (Gladman et al., 2003) and SLICC (systemic lupus international collaborating clinics) (Gladman et al., 1996) . Limitations of individual disease activity scores lead to the development of composite indices such as SLE responder index (SRI and SRI-50) (Mikdashi and Nived, 2015) (Castrejon et al., 2014) and the BILAG based composite lupus assessment (BLICA) (Castrejon et al., 2014) . The most commonly used patient reported outcome score is Scleroderma Scleroderma, also known as systemic sclerosis, is a rare autoimmune disease associated with significant morbidity and mortality. It is characterised by vascular injury and abnormal fibrotic processes that can affect multiple organ systems, including the skin, lungs, gastrointestinal (GI) tract and cardiovascular system. Skin involvement in scleroderma is almost universal. The modified Rodnan skin score (mRSS) (Clements et al., 1995) is a validated measure of skin disease and has become the most commonly used measure of disease activity in patients with systemic sclerosis. The mRSS correlates with patient derived measures of disease, physical function and mortality.
However, there is a high inter-observer variation in this score. Disease of the GI system occurs in approximately 90% of patients with scleroderma and has a major impact on their health-related quality of life. However, few instruments have been validated for the assessment of GI tract in scleroderma. Interstitial lung disease and pulmonary arterial hypertension are the leading cause of death in patients with scleroderma. Lung function tests and the 6 minute walk test are surrogate markers for these disease parameters in clinical trials. The 6 minute walk test measures the distance a patient can walk in six minutes and has been successfully incorporated into trials of scleroderma-related PAH (Badesch et al., 2000) . Raynaud's phenomenon (RP) occurs in more than 90% of patients with scleroderma and is measured using the RP score (Merkel et al., 2002) . Severe Raynaud's can lead to digital ulcers (DU). These are manually counted to provide a DU score. The HAQ I is a widely used patient reported outcome score used in rheumatic diseases (Fries et al., 1980) and has been validated in scleroderma. The scleroderma HAQ is a variation of the HAQ incorporating questions specific to scleroderma disease (Steen and Medsger, 1997) . (Clements et al., 1995) Skin thickness across 17 regions of the body. Clinician uses index finger and thumb to roll or gently pinch skin. A scale 0-3 is applied. 0-No thickening, 1-Mild thickening, 2-Moderate thickening, 3-Severe thickening Pulmonary function tests Vital capacity (VC), Forced vital capacity and Diffusing capacity for carbon monoxide are important variables in the assessment of lung involvement 6 minute walk test The 6-minute walk test (6MWT) measures the distance a person can walk in 6 minutes Raynaud's condition score (Merkel et al., 2002) The RCS is calculated from a summation of 1-or 2-week daily patient self-assessments of RP activity using a 0 to 10 ordinal scale. The RCS incorporates the cumulative daily frequency, duration, severity, and impact of RP attacks.
Digital ulceration count
Manual count of the number of digital ulcers Patient reported outcomes HAQ-DI (Fries et al., 1980) The HAQ-DI assesses eight disability categories over the past 7 days (dressing/grooming, arising, eating, walking, hygiene, reach, grip, common daily activities). Items are rated on a 4-point scale, ranging from 0 (without any difficulty) to 3 (unable to do), with higher scores indicating greater functional disability. The total score is the mean of the highest scores of each of the eight categories, ranging from 0 (no disability) to 3 (severe disability). (Steen and Medsger, 1997) Includes the disability and pain scales of the HAQ plus five visual analogue scales (VASs) that patients use to rate scleroderma-specific problems in the preceding week including pulmonary disease, digital ulcers, Raynaud's phenomenon, GI disease, and skin disease
The Scleroderma HAQ (SHAQ)

Inflammatory myopathies
The idiopathic inflammatory myopathies (IIM) are characterised by auto immune mediated muscle inflammation and weakness. They have a worldwide prevalence of 14 in 100,000 (Meyer et al., 2015) . Adult polymyositis (PM), dermatomyositis (DM), and juvenile dermatomyositis (JDM) are among the most frequent of the IIM. During the past decade, collaborations such as the International Myositis Assessment & Clinical Studies Group (IMACS) have undertaken projects to define core measures of disease activity and damage in myositis and dermatomyositis, and to develop and validate tools for these measures .
The most commonly-used tools include the Manual Muscle Test 8 (MMT8) (Miller et al., 2001) ; Myositis Intention to Treat (MITAX); and Myositis Disease Activity Assessment Tool (MYOACT) . Disease damage measures are used to assess the persistent change in anatomy, physiology, pathology or function resulting from previously active disease or complications of therapy. Usually, changes are post-inflammatory, cumulative and irreversible. Damage should be present for at least six months despite previous immunotherapy, rehabilitation or other therapy. The most commonly-used tool to assess disease damage is Myositis Damage Index (MDI) .
In addition to measuring myositis-specific activity and damage, Rider and colleagues (2011) also recommend the use of the following tools: general tools of global disease activity (e.g. physician and patient visual analogue scales -VAS); functional assessment tools (e.g. Health Activity Questionnaire -HAQ, and childhood myositis assessment score); and patientreported outcome measures (e.g. health-related quality of life measures such as SF36 for adults or CHQ-PF50 for children).  Part of the physical examination, requiring no specific equipment, to measure muscle strength.  A summary score assessing eight proximal, distal and axial muscles in the upper and lower extremities, using 0-10 point scale. Each muscle group tested is scored by using either the modified MRC or Kendall grading scale, depending on how much the muscle group can do in terms of moving against gravity or against applied pressure.
 Partially validated, it is used internationally and in all subsets of myositis including adult and juvenile PM and DM, as well as for a number of neuromuscular conditions.
 Extremely useful for long-term monitoring of myositis patients in both clinical and research settings. However, requires adequate training to perform and does not discriminate between activity and damage.
(Rider et al 2011) Extra-muscular assessment: Myositis Intention to Treat (MITAX)
 The MITAX assesses specific manifestations in seven organs or systems (constitutional, cutaneous, skeletal, gastrointestinal, pulmonary, cardiac, and muscle). Each clinical features is recorded using a scale of 0-4 (0 = not present; 1 = improving; 2 = the same; 3 = worse; 4 = new). The score is then converted using a scoring schema to an overall disease activity score for each system, which indicates the level of treatment needed.
Myositis Disease Activity Assessment Tool (MYOACT)
 Assesses severity of activity in each organ system with a 10-cm visual analogue scale (VAS), and a global extra-muscular VAS.
Assessment of myositis damage Myositis Damage Index (MDI)
 A comprehensive tool to assess the extent and severity of damage developing in 11 organs systems. A complete history and physical examination is needed, although minimal training required.
 Organ-specific questions ask the presence or absence of a given sign or symptom, and the overall rating of disease damage in each system using 10cm visual analogue scale to measure severity.
 The MDI can be used in both adult and juvenile PM and DM patients, although due to its comprehensive nature, may reflect damage caused by co-morbid conditions not just myositis.
Dermatomyositis
Myositis occurring with characteristic skin and nail manifestations is coined dermatomyositis (DM). These manifestations may include Gottron's papules, helitrope rash, photo-distributed erythema, poikiloderma, dilated nail fold capillaries, scalp involvement and calcinosis cutis. The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), is the most commonly used combined tool in clinical practice and therapeutic studies for DM (Klein et al., 2008) . It is a clinician scored instrument that measures skin activity and damage. Activity is measured in three areas -erythema, scale, and erosion/ulceration. Damage is measured in two areas -poikiloderma and calcinosis. In addition, Gottrons papules, periungual changes and alopecia are also scored. 
Sjӧgren's sydrome
Sjögren's syndrome (SS) is a chronic autoimmune disorder affecting approximately 0.1-0.4% of the general population with a female-to-male ratio of 9:1, usually diagnosed in the fourth and fifth decades of life (Daridon et al., 2007) . Clinically, SS is characterised by ocular and oral dryness developed because of the autoimmune infiltrating process affecting the exocrine glands. It may occur either alone, as primary SS, or in association with other autoimmune disease, often rheumatoid arthritis, systemic lupus erythematosus or systemic sclerosis, in which case is called secondary SS. Clinical, laboratory and histological features can be used to classify the systemic manifestations of SS as periepithelial or tissue-specific (including liver, lung and kidney) and extraepithelial (including vasculitis, peripheral neuropathy, renal involvement and myositis) (Fox et al., 1984) .
In the past decades, a core set of domains was defined to facilitate the complex assessment of SS patients' outcomes (Seror et al., 2012) . This included sicca symptoms, objective measurements of tear and saliva production, fatigue, quality of life, disease activity and damage indexes. Index (ESSPRI) (Seror et al., 2011) , and the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) (Seror et al., 2015) , a systemic activity index to assess systemic manifestations, which (Bowman et al., 2007)  Originated from the BILAG  Consists of 42 questions from 8 domains (constitutional, musculoskeletal, cutaneous/vascular, respiratory, neurological, renal, salivary gland, haematological)  Scored as new, same, worse, improving or not present Sjӧgren's Syndrome Disease Activity Index (SSDAI) (Vitali et al., 2007)  Assessment of disease activity  Eight domains: constitutional, salivary gland, articular, haematological, pleuro-pulmonary, vasculitis, renal, peripheral neuropathy EULAR Sjӧgren's Syndrome Disease Activity Index (ESSDAI) (Seror et al., 2015)  Assessment tool of disease activity in pSS  Twelve Domains: constitutional, lymphadenopathy and lymphoma, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, haematological, biological Damage indexes Sjӧgren's Syndrome Disease Damage Index (SSDDI) (Vitali et al., 2007)  Developed for the Italian cohort  Assessment of damage  Six domains: Oral/salivary damage, ocular damage, neurologic damage, pleuropulmonary, renal, lymphoproliferative Sjӧgren's Syndrome Damage Index (SSDI) (Barry et al., 2008)  Developed for the UK cohort  Assessment of damage  Ten domains: Ocular, oral, neurological, renal, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, endocrine, malignancy Patient reported outcomes EULAR Sjӧgren's Syndrome Patient Reported Index (ESSPRI) (Seror et al., 2011)  Derived from PROFAD-SSI  Patient questionnaire to assess symptoms rather than disease activity as the ESSDAI  Three questions regarding dryness, fatigue, pain  Scale of 0-10  Reported to be an independent predictor of health-related quality of life in pSS patients (Cho et al., 2013) .
PROFAD-SSI score (profile of fatigue and discomfort sicca symptoms inventory)  PROFAD-SSI score is a 64-point questionnaire that covers symptoms of somatic fatigue, mental fatigue, arthralgia, vascular symptoms, sicca (ocular and oral) symptoms, cutaneous and vaginal dryness  The PROFAD-SSI-SF (short form) score is a 19-point questionnaire abbreviated from the above which has been validated as a pSS outcome tool (Bowman et al., 2009 )  Fatigue VAS was found to most closely correlate with somatic fatigue  The somatic fatigue domain forms the PROF-S whilst the mental fatigue domain forms the PROF-M (derived from patient's descriptions of fatigue)
The ESSDAI and ESSPRI scores are currently used as gold standard in clinical trials. An ESSDAI ≥5 signifies moderately active disease, while a minimal clinically important improvement is defined as a decrease of at least 3 points (Seror et al., 2011 ). An ESSPRI score above 5 defines significant impact of SS associated symptoms on patients' quality of life (Cho et al., 2013) .
Both ESSDAI and ESSPRI are found to be sensitive to change (Meiners et al., 2012) ; therefore they are the most used outcome measures in SS.
Conclusions
A number of outcome measures have been validated for the assessment of rare rheumatologic diseases. The multi-systemic nature of these diseases pose a significant challenge to accurately capture the spectrum of disease activity and damage. Furthermore, the rarity of these diseases limits the power of validity and reproducibility assessments for outcome measures. As we advance our understanding of the pathogenesis of these diseases, and develop novel therapeutic targets, refinement of these outcome measures will become necessary.
